# KaNDy Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kandy-therapeutics

- Industry: Biotechnology
- Headquarters: UK
- Website: www.kandytherapeutics.com
- Total disclosed funding: $32M
- Latest round: Series C (Aug 24, 2018)
- Investors on record: 5

## About

KaNDy Therapeutics Ltd. is a UK-based biopharmaceutical company focused on developing innovative treatments for women's health issues, particularly targeting menopause-related symptoms with its proprietary drug candidates.KaNDy Therapeutics Ltd. is dedicated to advancing therapies for women’s health, specifically in menopause management. Founded in 2017 in the UK, the company has completed 2 deals as of August 2020. The most recent funding involved a TRADE SALE to Bayer AG for USD 425 mn, with additional milestone payments of up to USD 450 mn. The company’s headquarters is located in London. The founder's history is not publicly available, and there are no mentions of subsidiaries or prior mergers.KaNDy Therapeutics Ltd. specializes in developing pharmaceutical solutions aimed at alleviating menopausal symptoms in women. Their primary product candidate is designed to address various aspects of menopause, improving quality of life through innovative treatments that are backed by clinical research. The company is focused on bringing effective therapies to the global market, with particular emphasis on regions experiencing significant unmet needs in women's health.For the most recent year, KaNDy Therapeutics Ltd. reported an EBITDA of USD -95,503.1, indicating operational expenditures exceed revenues, which is typical for companies in early development stages in the biopharmaceutical sector.Following the acquisition by Bayer AG in September 2020, KaNDy Therapeutics Ltd. plans to leverage the resources and expertise of Bayer to accelerate the development and commercialization of its therapies. The funding received will be utilized to enhance research capabilities and expand into new markets, with a focus on North America and Europe by 2023. The company is committed to advancing its product pipeline to meet the growing demand for effective treatments in women's health.

## Funding rounds

- Series C, Aug 24, 2018, $32M — OrbiMed Advisors, Forbion, Longitude Capital, Fountain Healthcare Partners, Advent Life Sciences

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Forbion (https://capitalatlas.ai/funds/forbion) — Series C
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series C
- Fountain Healthcare Partners (https://capitalatlas.ai/funds/fountain-healthcare-partners) — Series C
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series C